 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk [0m
[34mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LISINOPRIL increase or decrease the risk [0m
[32mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LISINOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LISINOPRIL: adverse_reactions: ADVERSE REACTIONS Lisinopril and hydrochlorothiazide tablets have been evaluated for safety in [0m[1;31m930[0m[31m patients including [0m[1;31m100[0m[31m patients treated for [0m[1;31m50[0m[31m weeks or more.[0m
[31mIn clinical trials with lisinopril and hydrochlorothiazide tablets no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred have been limited[0m
[31mto those that have been previously reported with lisinopril or hydrochlorothiazide. The most frequent clinical adverse experiences in controlled trials [0m[1;31m([0m[31mincluding open label extensions[0m[1;31m)[0m[31m with any [0m
[31mcombination of lisinopril and hydrochlorothiazide tablets were: dizziness [0m[1;31m([0m[1;31m7.5[0m[31m%[0m[1;31m)[0m[31m, headache [0m[1;31m([0m[1;31m5.2[0m[31m%[0m[1;31m)[0m[31m, cough [0m[1;31m([0m[1;31m3.9[0m[31m%[0m[1;31m)[0m[31m, fatigue [0m[1;31m([0m[1;31m3.7[0m[31m%[0m[1;31m)[0m[31m and orthostatic effects [0m[1;31m([0m[1;31m3.2[0m[31m%[0m[1;31m)[0m[31m all of which were more common than in [0m
[31mplacebo-treated patients. Generally, adverse experiences were mild and transient in nature; but see WARNINGS regarding angioedema and excessive hypotension or syncope. LISINOPRIL: adverse_reactions: [0m
[31mDiscontinuation of therapy due to adverse effects was required in [0m[1;31m4.4[0m[31m% of patients principally because of dizziness, cough, fatigue and muscle cramps. Adverse experiences occurring in greater than one[0m
[31mpercent of patients treated with lisinopril plus hydrochlorothiazide in controlled clinical trials are shown below. Percent of Patients in Controlled Studies Clinical adverse experiences occurring in [0m
[1;31m0.3[0m[31m% to [0m[1;31m1.0[0m[31m% of patients in controlled trials included: Lisinopril-Hydrochlorothiazide [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m930[0m[1;31m)[0m[31m Incidence [0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m207[0m[1;31m)[0m[31m Incidence Dizziness [0m[1;31m7.5[0m[31m [0m[1;31m([0m[1;31m0.8[0m[1;31m)[0m[31m [0m[1;31m1.9[0m[31m Headache [0m[1;31m5.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m1.9[0m[31m [0m
[31mCough [0m[1;31m3.9[0m[31m [0m[1;31m([0m[1;31m0.6[0m[1;31m)[0m[31m [0m[1;31m1.0[0m[31m Fatigue [0m[1;31m3.7[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m1.0[0m[31m Orthostatic Effects [0m[1;31m3.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m. LISINOPRIL: adverse_reactions: [0m[1;31m0[0m[31m Diarrhea [0m[1;31m2.5[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Upper Respiratory Infection [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.0[0m[1;31m)[0m[31m [0m[1;31m0.0[0m[31m Muscle[0m
[31mCramps [0m[1;31m2.0[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Asthenia [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m [0m[1;31m1.0[0m[31m Paresthesia [0m[1;31m1.5[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.0[0m[31m Hypotension [0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Vomiting [0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Dyspepsia [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.0[0m[1;31m)[0m[31m [0m[1;31m0.0[0m[31m Rash [0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Impotence [0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m. LISINOPRIL: [0m
[31madverse_reactions: [0m[1;31m0[0m[31m Body as a Whole: Chest pain, abdominal pain, syncope, chest discomfort, fever, trauma, virus infection. Cardiovascular: Palpitation, orthostatic hypotension. Digestive: [0m
[31mGastrointestinal cramps, dry mouth, constipation, heartburn. Musculoskeletal: Back pain, shoulder pain, knee pain, back strain, myalgia, foot pain. Nervous/Psychiatric: Decreased libido, vertigo, [0m
[31mdepression, somnolence. Respiratory: Common cold, nasal congestion, influenza, bronchitis, pharyngeal pain, dyspnea, pulmonary congestion, chronic sinusitis, allergic rhinitis, pharyngeal discomfort. [0m
[31mSkin: Flushing, pruritus, skin inflammation, diaphoresis. Special Senses: Blurred vision, tinnitus, otalgia. Urogenital: Urinary tract infection. LISINOPRIL: adverse_reactions: Angioedema: Angioedema [0m
[31mhas been reported in patients receiving PRINZIDE, with an incidence higher in Black than in non-Black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, [0m
[31mextremities, lips, tongue, glottis and/or larynx occurs, treatment with PRINZIDE should be discontinued and appropriate therapy instituted immediately. In rare cases, intestinal angioedema has been [0m
[31mreported with angiotensin converting enzyme inhibitors including lisinopril. [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. Hypotension: In clinical trials, adverse effects relating to hypotension occurred as follows: hypotension [0m
[1;31m([0m[1;31m1.4[0m[31m percent[0m[1;31m)[0m[31m, orthostatic hypotension [0m[1;31m([0m[1;31m0.5[0m[31m percent[0m[1;31m)[0m[31m, other orthostatic effects [0m[1;31m([0m[1;31m3.2[0m[31m percent[0m[1;31m)[0m[31m. In addition syncope occurred in [0m[1;31m0.8[0m[31m percent of patients [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. LISINOPRIL: adverse_reactions: [0m
[31mCough: See PRECAUTIONS - Cough . Clinical Laboratory Test Findings Serum Electrolytes: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Creatinine, Blood Urea Nitrogen: Minor reversible increases in blood urea nitrogen and serum [0m
[31mcreatinine were observed in patients with essential hypertension treated with lisinopril and hydrochlorothiazide tablets. More marked increases have also been reported and were more likely to occur in[0m
[31mpatients with renal artery stenosis [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and Calcium: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Hemoglobin and Hematocrit: Small decreases in [0m
[31mhemoglobin and hematocrit [0m[1;31m([0m[31mmean decreases of approximately [0m[1;31m0.5[0m[31m g% and [0m[1;31m1.5[0m[31m vol%, respectively[0m[1;31m)[0m[31m occurred frequently in hypertensive patients treated with lisinopril and hydrochlorothiazide tablets but [0m
[31mwere rarely of clinical importance unless another cause of anemia coexisted. LISINOPRIL: adverse_reactions: In clinical trials, [0m[1;31m0.4[0m[31m% of patients discontinued therapy due to anemia. Liver Function [0m
[31mTests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. [0m[1;31m([0m[31mSee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m. Other adverse reactions that have been reported with the individual components are [0m
[31mlisted below: Lisinopril - In clinical trials adverse reactions which occurred with lisinopril were also seen with lisinopril and hydrochlorothiazide tablets. LISINOPRIL: adverse_reactions: In [0m
[31maddition, and since lisinopril has been marketed, the following adverse reactions have been reported with lisinopril and should be considered potential adverse reactions for lisinopril and [0m
[31mhydrochlorothiazide tablets: Body as a Whole: Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, Anaphylactoid and Possibly Related Reactions [0m[1;31m)[0m[31m, malaise, edema, facial edema, pain, pelvic pain, flank pain, [0m
[31mchills; Cardiovascular: Cardiac arrest, myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m, pulmonary [0m
[31membolism and infarction, worsening of heart failure, arrhythmias [0m[1;31m([0m[31mincluding tachycardia, ventricular tachycardia, atrial tachycardia, atrial fibrillation, bradycardia, and premature ventricular [0m
[31mcontractions[0m[1;31m)[0m[31m, angina pectoris, transient ischemic attacks LISINOPRIL: adverse_reactions: , paroxysmal nocturnal dyspnea, decreased blood pressure, peripheral edema, vasculitis; Digestive: [0m
[31mPancreatitis, hepatitis [0m[1;31m([0m[31mhepatocellular or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, gastritis, anorexia, flatulence, increased salivation; Endocrine: Diabetes mellitus, syndrome of [0m
[31minappropriate antidiuretic hormone secretion [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m; Hematologic: Rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported. LISINOPRIL: adverse_reactions: Hemolytic [0m
[31manemia has been reported; a causal relationship to lisinopril cannot be excluded; Metabolic: Gout, weight loss, dehydration, fluid overload, weight gain; Musculoskeletal: Arthritis, arthralgia, neck [0m
[31mpain, hip pain, joint pain, leg pain, arm pain, lumbago; Nervous System/Psychiatric: Ataxia, memory impairment, tremor, insomnia, stroke, nervousness, confusion, peripheral neuropathy [0m[1;31m([0m[31me.g. [0m
[31mLISINOPRIL: adverse_reactions: paresthesia, dysesthesia[0m[1;31m)[0m[31m, spasm, hypersomnia, irritability, mood alterations [0m[1;31m([0m[31mincluding depressive symptoms[0m[1;31m)[0m[31m; hallucinations ; Respiratory: Malignant lung neoplasms, [0m
[31mhemoptysis, pulmonary edema, pulmonary infiltrates, eosinophilic pneumonitis, bronchospasm, asthma, pleural effusion, pneumonia, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, [0m
[31msinusitis, pharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; Skin: Urticaria, alopecia, herpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema, psoriasis.     [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: pharmacokinetics: Pharmacokinetics and Metabolism Following oral administration of lisinopril, peak serum concentrations occur within about [0m[1;31m7[0m[31m hours. Declining serum concentrations[0m
[31mexhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not[0m
[31mappear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of [0m
[31mlisinopril is approximately [0m[1;31m25[0m[31m percent, with large intersubject variability [0m[1;31m([0m[1;31m6[0m[31m% to [0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m at all doses tested [0m[1;31m([0m[1;31m5[0m[31m mg to [0m[1;31m80[0m[31m mg[0m[1;31m)[0m[31m. Lisinopril absorption is not influenced by the presence of food in the [0m
[31mgastrointestinal tract. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of [0m[1;31m12[0m[31m hours. LISINOPRIL: pharmacokinetics: Impaired renal function decreases elimination of [0m
[31mlisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below [0m[1;31m30[0m[31m mL/min. Above this glomerular [0m
[31mfiltration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to attain [0m
[31msteady state is prolonged. Older patients, on average, have [0m[1;31m([0m[31mapproximately doubled[0m[1;31m)[0m[31m higher blood levels and area under the plasma concentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m than younger patients. [0m[1;31m([0m[31mSee DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. Multiple doses of lisinopril in rats do not result in [0m
[31maccumulation in any tissues. However, milk of lactating rats contains radioactivity following administration of [0m[1;31m14[0m[31m C lisinopril. LISINOPRIL: pharmacokinetics: By whole body autoradiography, [0m
[31mradioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: pharm_class_cs         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: package_ndc         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: product_ndc         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: pharm_class_pe         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: spl_id         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: clinical_pharmacology: [0m[1;31m1[0m[31m mEq/L; however, approximately [0m[1;31m15[0m[31m percent of patients had increases greater than [0m[1;31m0.5[0m[31m mEq/L and approximately six percent had a decrease greater than [0m[1;31m0.5[0m[31m [0m
[31mmEq/L. In the same study, patients treated with lisinopril plus a thiazide diuretic showed essentially no change in serum potassium. [0m[1;31m([0m[31mSee PRECAUTIONS .[0m[1;31m)[0m[31m ACE is identical to kininase, an enzyme that [0m
[31mdegrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated. While the mechanism through [0m
[31mwhich lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low-renin hypertension.[0m
[31mLISINOPRIL: clinical_pharmacology: Although lisinopril was antihypertensive in all races studied, Black hypertensive patients [0m[1;31m([0m[31musually a low-renin hypertensive population[0m[1;31m)[0m[31m had a smaller average [0m
[31mresponse to lisinopril monotherapy than non-Black patients. Pharmacokinetics and Metabolism Following oral administration of lisinopril, peak serum concentrations occur within about [0m[1;31m7[0m[31m hours. Declining[0m
[31mserum concentrations exhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to [0m
[31mdose. Lisinopril does not appear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent[0m
[31mof absorption of lisinopril is approximately [0m[1;31m25[0m[31m percent, with large intersubject variability [0m[1;31m([0m[1;31m6[0m[31m% to [0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m at all doses tested [0m[1;31m([0m[1;31m5[0m[31m mg to [0m[1;31m80[0m[31m mg[0m[1;31m)[0m[31m. LISINOPRIL: clinical_pharmacology: Lisinopril absorption [0m
[31mis not influenced by the presence of food in the gastrointestinal tract. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of [0m[1;31m12[0m[31m hours. Impaired renal function decreases[0m
[31melimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below [0m[1;31m30[0m[31m mL/min. Above this [0m
[31mglomerular filtration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to [0m
[31mattain steady state is prolonged. Older patients, on average, have [0m[1;31m([0m[31mapproximately doubled[0m[1;31m)[0m[31m higher blood levels and area under the plasma concentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m than younger patients. [0m[1;31m([0m[31mSee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. LISINOPRIL: clinical_pharmacology: Multiple [0m
[31mdoses of lisinopril in rats do not result in accumulation in any tissues. However, milk of lactating rats contains radioactivity following administration of [0m[1;31m14[0m[31m C lisinopril. By whole body [0m
[31mautoradiography, radioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses. Pharmacodynamics Administration of lisinopril to [0m
[31mpatients with hypertension results in a reduction of supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is usually not [0m
[31mobserved although it can occur and should be anticipated in volume and/or salt-depleted patients. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In most patients studied, onset of antihypertensive activity was seen at one hour [0m
[31mafter oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by six hours. LISINOPRIL: clinical_pharmacology: In some patients achievement of optimal [0m
[31mblood pressure reduction may require two to four weeks of therapy. At recommended single daily doses, antihypertensive effects have been maintained for at least [0m[1;31m24[0m[31m hours, after dosing, although the [0m
[31meffect at [0m[1;31m24[0m[31m hours was substantially smaller than the effect six hours after dosing. The antihypertensive effects of lisinopril have continued during long-term therapy. Abrupt withdrawal of lisinopril[0m
[31mhas not been associated with a rapid increase in blood pressure; nor with a significant overshoot of pretreatment blood pressure. In hemodynamic studies in patients with essential hypertension, blood [0m
[31mpressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive patients, following [0m
[31madministration of lisinopril, there was an increase in mean renal blood flow that was not significant.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: geriatric_use: Geriatric Use Clinical studies of lisinopril and hydrochlorothiazide tablets did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether [0m
[31mthey respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for [0m
[31man elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant [0m
[31mdisease or other drug therapy. In a multiple-dose pharmacokinetic study in elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide combination, area under the plasma [0m
[31mconcentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m increased approximately [0m[1;31m120[0m[31m% for lisinopril and approximately [0m[1;31m80[0m[31m% for hydrochlorothiazide in older patients. LISINOPRIL: geriatric_use: This drug is known to be [0m
[31msubstantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased [0m
[31mrenal function, care should be taken in dose selection. Evaluation of the hypertensive patient should always include assessment of renal function. [0m[1;31m([0m[31mSee DOSAGE AND ADMINISTRATION.         [0m
[31mSOURCE:LISINOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LISINOPRIL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The adverse reactions section [0m
[32mlists various gastrointestinal issues such as diarrhea, nausea, vomiting, dyspepsia, gastrointestinal cramps, dry mouth, constipation, heartburn, pancreatitis, hepatitis, gastritis, anorexia, and [0m
[32mflatulence, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization.[0m

[32mEXTRACT_START_END: [0m[32m...[0m[32madverse reactions section lists various gastrointestinal issues such as diarrhea, nausea, vomiting, dyspepsia[0m[32m...[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the [0m
[34mLISINOPRIL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The adverse reactions section lists various gastrointestinal issues such [0m
[34mas diarrhea, nausea, vomiting, dyspepsia, gastrointestinal cramps, dry mouth, constipation, heartburn, pancreatitis, hepatitis, gastritis, anorexia, and flatulence, but there is no direct mention of [0m
[34mgastrointestinal ulcers or their potential to lead to hospitalization.[0m

[34mEXTRACT_START_END: [0m[34m...[0m[34madverse reactions section lists various gastrointestinal issues such as diarrhea, nausea, vomiting, dyspepsia[0m[34m...[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LISINOPRIL increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the LISINOPRIL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists various [0m
[32mgastrointestinal issues, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LISINOPRIL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LISINOPRIL increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the LISINOPRIL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists various [0m
[34mgastrointestinal issues, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LISINOPRIL increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LISINOPRIL increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the LISINOPRIL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label lists various gastrointestinal [0m
[31missues, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of gastrointestinal ulcer hospitalization. The label lists various gastrointestinal issues, but there is no [0m
[32mdirect mention of gastrointestinal ulcers or their potential to lead to hospitalization.[0m
